When Maria, a 52-year-old teacher from Milan, joined the EloraTZP trial, she weighed 105 kilograms and struggled daily with fatigue, joint pain, and the constant worry of her rising blood sugar. After 48 weeks on the highest dose of the new drug combo, she lost 24.6 kilograms—nearly a quarter of her body weight—and her blood sugar stabilized like never before. Her story mirrors that of hundreds in a groundbreaking study unveiled at the 2026 European Association for the Study of Diabetes meeting, offering fresh hope to millions living with obesity and type 2 diabetes.
These two conditions often travel together, trapping people in a cycle that’s hard to break. But the new investigational drug EloraTZP—combining eloralintide and tirzepatide—targets multiple hormones involved in hunger and blood sugar control. In a 48-week trial of 367 adults, the combo didn’t just nudge the needle—it moved the mountain. At the highest dose, patients lost an average of 23.3% of their body weight, the equivalent of 24.6 kilograms (54.2 pounds), from a starting average of 105.4 kilograms (232.4 pounds).
The benefits went beyond the scale. Participants also saw their HbA1c—a key marker of long-term blood sugar control—drop by an average of 2.9 percentage points, from a starting average of 8.1%. Even the lowest dose brought a 13.2% weight loss and a 2.2% drop in HbA1c, both clinically significant improvements. The drug combo is given as two separate pen injections, and all four tested doses met their primary and secondary goals, showing consistent results across the board.
Side effects were mostly mild to moderate gastrointestinal issues, like nausea or upset stomach, and tended to occur during the dose ramp-up period. Still, the safety profile was manageable, and no major red flags emerged. For Dr. Liana K. Billings, lead author and researcher at Endeavor Health in Evanston, Illinois, the results signal a shift in how we treat complex metabolic diseases.
"Obesity and type 2 diabetes are interconnected, and we are seeing the potential benefit of targeting multiple hormonal pathways to address both," she said. The body doesn’t rely on just one signal to manage hunger and sugar—so why should medicine? By combining a selective amylin receptor agonist (eloralintide) with a dual GIP/GLP-1 receptor agonist (tirzepatide), EloraTZP mimics the body’s natural response to food more closely than single-pathway drugs.
If future trials confirm these results, EloraTZP could become a powerful new tool for doctors and patients. For now, the data stand as a beacon of progress—proof that science is moving beyond one-size-fits-all solutions. As researchers continue refining treatments that reflect the real, messy complexity of human metabolism, millions may soon have access to therapies that don’t just manage symptoms, but transform lives.